Clonal hematopoiesis is associated with hematological toxicity during lenalidomide-based therapy for MCL

Leukemia. 2022 Dec;36(12):2912-2916. doi: 10.1038/s41375-022-01725-8. Epub 2022 Oct 23.

Simon Husby^{1

2}, Cecilie Bæch-Laursen^{3

4}, Christian W Eskelund^{3

4}, Francesco Favero^{4

5}, Jakob Schmidt Jespersen^{4

5}, Martin Hutchings³, Lone Bredo Pedersen³, Carsten U Niemann^{3

6}, Joachim Weischenfeldt^{4

5}, Riikka Räty⁷, Thomas Stauffer Larsen^{8

9}, Arne Kolstad¹⁰, Mats Jerkeman¹¹, Kirsten Grønbæk^{3

4

6}

¹ Department of Hematology, Rigshospitalet, Copenhagen, Denmark. simon.husby.01@regionh.dk.
² Biotech Research and Innovation Center (BRIC), University of Copenhagen, Copenhagen, Denmark. simon.husby.01@regionh.dk.
³ Department of Hematology, Rigshospitalet, Copenhagen, Denmark.
⁴ Biotech Research and Innovation Center (BRIC), University of Copenhagen, Copenhagen, Denmark.
⁵ Finsen Laboratory, Rigshospitalet, Copenhagen, Denmark.
⁶ Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.
⁷ Department of Hematology, Helsinki University Central Hospital, Helsinki, Finland.
⁸ Department of Hematology, Odense University Hospital, Odense, Denmark.
⁹ Centre for Cellular Immunotherapy of Haematological Cancer Odense (CITCO), Odense University Hospital, Odense, Denmark.
¹⁰ Department of Oncology, Innlandet Hospital, Lillehammer, Norway.
¹¹ Department of Oncology, Lund University Hospital, Lund, Sweden.

No abstract available

Publication types